Role of neuromedin U in accelerating of non-alcoholic steatohepatitis in mice

Publication date: Available online 7 October 2017
Source:Peptides
Author(s): Hitoshi Teranishi, Masafumi Hayashi, Ryoko Higa, Kenji Mori, Takashi Miyazawa, Jun Hino, Yuichiro Amano, Ryuichi Tozawa, Takanori Ida, Toshikatsu Hanada, Mikiya Miyazato, Reiko Hanada, Kenji Kangawa, Kazuwa Nakao
Neuromedin U (NMU), a neuropeptide originally isolated from porcine spinal cord, has multiple physiological functions and is involved in obesity and inflammation. Excessive fat accumulation in the liver leads to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which is closely associated with obesity. NAFLD and NASH develop and progress via complex pathophysiological processes, and it remains unclear to what extend the NMU system contributes to the risk of obesity-related disorders such as NAFLD and NASH. Here, we demonstrate that the NMU system plays a role in NAFLD/NASH pathogenesis. In the normal mouse liver, NMU mRNA was not detectable, and expression of the mRNA encoding neuromedin U receptor 1 (NMUR1), the peripheral receptor of NMU, was low. However, the expression of both was significantly increased in the livers of NASH mice. Furthermore, overproduction of NMU induced the mouse liver by hydrodynamic injection, exacerbated NASH pathogenesis. These data indicate a novel role for the peripheral NMU system, providing new insights into the pathogenesis of NAFLD/NASH.



http://ift.tt/2xpEvgU